AlphAIAlphAI — Financial news for AI agents
yahoo.com$SCTX

Scribe secures $129M in a rare gene editing IPO

Scribe Therapeutics raised about $129M in its IPO, selling 8.58M shares at $15 each, above earlier projections, and will start trading Friday on Nasdaq as SCTX. The article notes biotech IPO activity in 2026 and compares Scribe’s smaller, earlier-stage gene-editing focus to recent larger offerings.

Original reporting
yahoo.com
Published Jul 25, 2026, 4:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 25, 2026, 4:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Scribe secures $129M in a rare gene editing IPO — source image
Source · yahoo.com
Decision brief

The 30-second read

$SCTXBullishMed
01

Why it matters

The immediate tradable element is the IPO pricing and Nasdaq start date for SCTX, which can drive short-term volatility and positioning in early-stage gene-editing exposure.

02

Market read

This is a primary capital-markets event for SCTX, offering a concrete entry point for IPO-focused trading and risk management around first liquidity.

03

What to watch

First-day performance will hinge on demand versus the $15 offer price, lockup expectations, and whether investors view the epigenetic approach as differentiated enough for cardiometabolic scale.

Relevance 8/10Novelty 8/10Timing: Shares begin trading Friday on Nasdaq after Thursday IPO pricing.

Background

The article frames Scribe as the first gene-editing company to IPO since Metagenomi’s $94M offering in Feb 2024, amid a broader 2026 biotech IPO rebound.

Company-level read

Ticker impact

$SCTXBullishMedium confidence
Context

Scribe Therapeutics sold 8.58M shares at $15 and will begin trading Friday on Nasdaq under SCTX, signaling a fresh IPO setup.

Expected impact

Near-term volatility likely elevated around first trade as investors reprice gene-editing risk versus the $15 offer price.

Evidence & confidence

The article discloses the priced deal size, offer price, and first trading date, but provides no post-IPO guidance or clinical readout beyond early-stage framing.

Market effects

Sector

A successful, albeit smaller, gene-editing IPO may improve sentiment for rare-condition gene-editing peers and future IPO pipeline.

Regional

Primarily US Nasdaq flow, with limited direct regional spillover beyond biotech risk appetite.

Global

Gene-editing remains a global investor theme; IPO activity can influence cross-border funding expectations for similar platforms.

Counterpoint

What could challenge this read

Smaller-than-median gene-editing IPOs may still face post-listing valuation compression if investors discount limited late-stage assets.

Key entities

  • company
    Scribe Therapeutics

    Gene-editing developer that priced its IPO at $15 and will start trading Friday as SCTX.

  • venue
    Nasdaq

    Exchange where SCTX shares are scheduled to begin trading Friday.

Read at source← All news

Related articles

$SCTXMedAI 9/10

One Shot, Two Years of Lower Cholesterol: Scribe’s CRISPR Gene Therapy Begins Human Trials

Scribe Therapeutics (SCTX) presented data at AHA 2026 showing its gene therapy STX-1150 maintained LDL cholesterol control for two years in non-human primates. The therapy uses epigenetic gene silencing to target PCSK9. Separately, Scribe's STX-1200, a CRISPR-based LPA gene editor, showed durable Lp(a) reduction in preclinical models. Novartis' pelacarsen failed to reduce cardiovascular events in a Phase 3 trial, impacting competitors.

techtimes.com
$SCTXHigh

Scribe Therapeutics Reports Second Quarter 2026 Financial Results

Scribe Therapeutics, Inc. (SCTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to d

SEC EDGAR 8-K
$LLYMed

Eli Lilly Discloses Investment at Scribe Therapeutics with 7.36% Stake

Eli Lilly and Company disclosed a 7.36% stake in Scribe Therapeutics, Inc. common stock. The position combines shares from a July 10, 2026 conversion of an 8% convertible note and 333,333 shares bought in Scribe’s July 23, 2026 IPO, according to a Schedule 13D filed on Jul. 30, 2026. The move links a major pharmaceutical company to Scribe following its IPO and signals potential engagement.

tradingview.com
$ANTLow

Anthropic lowers its estimated valuation ahead of its Nasdaq listing, amid market turbulence and concerns about AI investments

Anthropic has lowered its expected valuation for its upcoming Nasdaq listing to between $1 trillion and $1.25 trillion, down from a previously considered $1.5 trillion. The company, which will list under the ticker ANT, had initially targeted a market capitalization of up to $2 trillion in October, after a $965 billion private valuation in May. The revision follows a challenging period for the tech sector, with the Nasdaq index experiencing significant declines.

informat.ro